Technology evaluation: TG-1031, Transgene SA.
Tumor-associated antigens have considerable promise not only as diagnostic or prognostic markers but also as targets for active or passive immunotherapy. The epithelial mucin MUC1 is a transmembrane molecule which is expressed by most glandular epithelial cells. Transgene has developed VV-MUC1-IL-2 (TG-1031), an antigen-specific therapy, involving the tumor antigen MUC1 and the cytokine IL-2 combined with a vaccinia virus vector. Vaccinia virus vectors have been shown to stimulate a strong immune response to encoded antigens in vivo. This therapy has potential for the treatment of breast cancer, prostate cancer and other adenocarcinomas and is currently under investigation in phase I and II trials.
Department of Urology, Medical University of Luebeck, Ratzeburger Allee 160, 23538 Luebeck, Germany. doehn@medinf.mu-luebeck.de
C
C
Doehn
D
D
Jocham
D000818:Animals; D001709:Biotechnology; D001943:Breast Neoplasms / Q000628:therapy; D019496:Cancer Vaccines / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use*; D005260:Female; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D007376:Interleukin-2 / Q000235:genetics / Q000276:immunology*; D008297:Male; D051379:Mice; D018396:Mucin-1 / Q000235:genetics / Q000276:immunology*; D011471:Prostatic Neoplasms / Q000628:therapy; D014616:Vaccinia virus / Q000235:genetics
D019496:Cancer Vaccines; D007376:Interleukin-2; D018396:Mucin-1